Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00669825
Other study ID # ALV003-0812
Secondary ID
Status Completed
Phase Phase 1
First received April 21, 2008
Last updated February 17, 2010
Start date March 2008
Est. completion date October 2008

Study information

Verified date February 2010
Source Alvine Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

ALV003-0812 is a study of the safety and tolerability of a study drug (ALV003) in healthy adult volunteers and in patients with well-controlled celiac disease, following a meal that contains gluten.


Description:

ALV003-0812 (the FED study) is designed to evaluate the safety and tolerability of a single dose of the study drug, ALV003, administered at one of four different dose levels, and following a test meal containing a small amount (1 gram) of gluten. ALV003 has been demonstrated to proteolyze (assist with the digestion of) various forms of gluten (gluten flour, wheat bread) in laboratory studies and in animals. Celiac disease has been estimated to affect 1% of the population of the United States, is related to gluten, and has a wide range of clinical manifestations including chronic gastrointestinal symptoms, malabsorption, and bone disease.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date October 2008
Est. primary completion date October 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Ages 18 to 45 years (inclusive)

- Healthy volunteers, in good health on the basis of medical history, physical examination, and laboratory values to include: hematology, chemistry, urinalysis, and liver function tests.

- Subjects with well-controlled celiac disease (CD), in good health with the exception of CD

1. history of biopsy-proven CD in past 5 years

2. on gluten free diet for at least 8 weeks prior to enrollment

3. tTG or DGP titers within normal limits (= 15 IU)

4. no flare in symptoms for the past 8 weeks

- Male or non-lactating, non-pregnant females who are postmenopausal, sterile or using at least two acceptable and highly effective birth control methods

- No systemic biologics may be taken for at least 6 months prior to Visit 2 and through 24 hours post-dose at Visit 3 Other than birth control, no prescribed medications, NSAIDs or aspirin may be taken for at least 7 days prior to Visit 2 and through 24 hours post-dose at Visit 3.

- No probiotics may be taken for at least 5 days prior to Visit 2 and through 24 hours post-dose at Visit 3.

- No over-the-counter medications and supplements may be taken for at least 3 days prior to Visit 2 and through 24 hours post-dose at Visit 3

- Body Mass Index of < 30 kg/m2

- Have understood and signed an Informed Consent Form

- Able and willing to comply with study requirements

Exclusion Criteria:

- Positive urine test for alcohol or illegal drugs at screening

- Positive breath test for Helicobacter pylori

- History (within the last 5 years) of inadequate acid secretion, either through a pentagastrin stimulated acid secretion test or fasting intragastric pH 2.5 or greater assessed by passage of a gastric pH probe in the fasting condition

- Aspirin or nonsteroidal anti-inflammatory drugs within 7 days prior to nasogastric or orogastric intubation at Visit 2

- The subject has received an experimental drug within 30 days

- History of substance abuse within the past 5 years

- Clinically significant abnormal lab values, as determined by the PI

1. Liver Function Tests > 2.5 times Upper Limit of Normal (ULN)

2. Serum Creatinine > 1.5 mg/dL

3. Hemoglobin (Hb) < 10 g/dL

4. Hematocrit outside of the normal range

5. Platelet count < 150,000

6. Serum Potassium, Prothrombin Time (PT), Partial Thromboplastin Time (PTT), or white blood cell count (WBC) outside of the normal range

- History of tobacco use within the last 6 months

- History of untreated or active peptic ulcer disease, esophagitis, motility disorders or any GI diseases in the past year

- Chronic use (more than once a week) of antacids, H2 receptor blockers or proton pump inhibitors

- Alcohol consumption of > 2 standard drinks equivalents per day

- Positive pregnancy test within 7 days prior to study drug administration

- Medical history (Healthy volunteers)

1. gluten intolerance

2. first degree relative diagnosed with celiac disease

3. history of food allergies or digestive enzyme deficiencies

4. history of any medically significant condition considered by PI to adversely affect participation

5. chronic disease or condition

- Medical History (well-controlled CD subjects)

1. history of any medically significant condition (other than CD) considered by PI to adversely affect participation

2. chronic disease or condition other than CD

3. history of severe reactions to low doses of gluten/accidental exposure to gluten

- History of a condition that is contraindicated for nasogastric or orogastric intubation

- Known allergy or hypersensitivity to any of the components of the test meal, placebo, study drug, E. coli-derived proteins or the 25% dextrose and water solution that will be used to flush the tube immediately following dosing

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
ALV003
Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
Placebo
Placebo to be administered via intragastric tube

Locations

Country Name City State
United States Clinical Applications Laboratories San Diego California
United States Clinical Applications Laboratories, Inc. San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Alvine Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability Throughout Yes
See also
  Status Clinical Trial Phase
Completed NCT04349904 - Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Completed NCT04593251 - Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis Phase 1
Completed NCT05810441 - Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
Recruiting NCT05555446 - Bovine Colostrum to Prevent Absorption of Gluten Early Phase 1
Completed NCT02754609 - Hookworm Therapy for Coeliac Disease Phase 1
Terminated NCT01902368 - Celiac Disease Screening N/A
Completed NCT02472704 - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo N/A
Completed NCT02312349 - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
Completed NCT01172665 - Celiac Disease Database
Completed NCT01100099 - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Phase 2/Phase 3
Completed NCT00639444 - Risk of Celiac Disease and Age at Gluten Introduction N/A
Active, not recruiting NCT05425446 - Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients Phase 1
Enrolling by invitation NCT02202681 - Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule N/A
Completed NCT00362856 - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects Phase 2
Terminated NCT03866538 - Budesonide in Patients With Immune Mediated Enteropathies Phase 4
Recruiting NCT05135923 - Glutenfree, Gut Microbiota and Metabolic Regulation N/A
Completed NCT05052164 - Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women N/A
Completed NCT03775499 - Probiotic BL NCC 2705 and Gluten Sensitivity N/A
Completed NCT03707730 - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease Phase 2

External Links